Clinical trials: Radiation-Induced Neoplasms
Prostate Cancer
Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
The primary objective of this trial is to examine the value of prophylactic versus therapeutic breast radiotherapy in Casodex monotherapy induced gynaecomastia and/or breast pain.
- Trial name
- COMART (NCT00590213)
- Testing
- Casodex 150mg, Radiotherapy, Haematology
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 125 people
- Sponsor
- AstraZeneca
Chemotherapy- and/or Radiation-induced Oral Mucositis
A Trial of Episil® Oral Liquid in Cancer Patients Suffering From Chemotherapy- and/or Radiation-induced Oral Mucositis
This is a randomized, multi-center, single-use, active-controlled, two-stage open study of episil®. The purpose of this study is to assess the local analgesic effect of episil® in cancer patients suffering from chemotherapy…
- Trial name
- NCT03546985
- Testing
- episil®, Kang Su
- Where
- 7 sites in China
- Volunteers
- 60 people
- Sponsor
- Solasia Pharma K.K.
Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
This study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
- Trial name
- AQUAx2 (NCT05926765)
- Testing
- AAV2-hAQP1 Concentration 1, AAV2-hAQP1 Concentration 2, AAV2-hAQP1 Concentration 3
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 290 people
- Sponsor
- MeiraGTx, LLC
Radiation Induced Mucositis in Head and Neck Cancer
A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation With or Without P276-00
A Clinical Study to Assess Radiation Induced Mucositis in Subjects with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT01903018
- Testing
- P276-00, Radiation Therapy, Cisplatin
- Where
- 7 sites in India
- Volunteers
- 73 people
- Sponsor
- Piramal Enterprises Limited
Oral Mucositis
Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer
The purpose of this study is to determine whether an oral rinse composed of botanical extracts is effective in the prevention of severe inflammation of the lining of the oral cavity caused by chemotherapy and radiation therapy…
- Trial name
- NCT01400620
- Testing
- IZN-6N4
- Where
- 10 sites in United States, Israel
- Volunteers
- 110 people
- Sponsor
- Izun Pharma Ltd
Oral Mucositis
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Oral Mucositis
The initial proposed clinical study will be conducted in adult head and neck cancer subjects. This will be an open-labeled, proof of concept trial to evaluate the efficacy, safety and tolerability of EISO in a form of oral rinse…
- Trial name
- NCT02399228
- Testing
- 0.25% EISO mouth rinse
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Santalis Pharmaceuticals, Inc.
Non Small Cell Lung Cancer
A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer
This trial investigates pemetrexed and cisplatin followed by pemetrexed and cisplatin in combination with radiotherapy in participants with locally advanced, non-small cell lung cancer (NSCLC).
- Trial name
- NCT01000480
- Testing
- Pemetrexed, Cisplatin, Thoracic Radiotherapy
- Where
- 21 sites in France, Germany and 2 more
- Volunteers
- 90 people
- Sponsor
- Eli Lilly and Company
Mucositis, Nephrotoxicity
Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients.
- Conditions
- Mucositis, Nephrotoxicity, Ototoxicity
- Trial name
- NCT03480971
- Testing
- Tempol
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Matrix Biomed, Inc.
Metastatic Colorectal Cancer
A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer
The purpose of this study is to investigate the safety and effects of IMM 101 in combination with a single targeted dose of radiation in patients with metastatic colorectal cancer in whom chemotherapy or other treatment has not…
- Trial name
- NCT01539824
- Testing
- Mycobacterium obuense, SBRT
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- Immodulon Therapeutics Ltd
Radiodermatitis, Quality of Life
Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid®
To evaluate the performance of Xonrid® in the prevention and treatment of G2 radiation dermatitis in breast and head \& neck cancer patients.
- Trial name
- NCT03255980
- Testing
- Xonrid® gel, Standard of Care
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Helsinn Healthcare SA
Radiation-Induced Mucositis, Head and Neck Cancer
Benzydamine Oromucosal Solution in Oral Mucositis (BOOM)
The aim of the present study is to collect data on the feasibility of a preventative/therapeutic approach of radiation-induced oral mucositis with benzydamine oromucosal solution (mouthwash) in patients with head and neck cancer.
- Trial name
- BOOM (NCT05055726)
- Testing
- Benzydamine Hydrochloride 0.15% w/v oromucosal solution
- Where
- 10 sites in Hungary, Poland
- Volunteers
- 100 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Locally Advanced Pancreatic Cancer
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
- Trial name
- TIGeR-PaC (NCT03257033)
- Testing
- Gemcitabine, nab-paclitaxel, RenovoCath
- Where
- 31 sites in United States, Belgium
- Volunteers
- 190 people
- Sponsor
- RenovoRx
Cardiotoxicity, Heart Failure
Novel On-body Evaluation of Cardiac Health for Oncology
The goal of this study is to develop a wearable sensor system that can estimate left ventricular ejection fraction (LVEF), which is a measurement of the heart's function.
- Trial name
- NOECHO (NCT07158450)
- Where
- 11 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Skribe Medical
Radiation Dermatitis
LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients
The study will evaluate the safety, tolerability and efficacy of LUT014 gel topically administered in breast cancer patients who developed radiation dermatitis.
- Trial name
- NCT04261387
- Testing
- LUT014 Gel
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Lutris Pharma Ltd.
Lung Cancer
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent RT and maintenance osimertinib in chemotherapy ineligible or refusal adult patients with Stage III…
- Trial name
- NSCLC (NCT07295821)
- Testing
- Osimertinib
- Where
- 20 sites in China
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Radiation Induced Oral Mucositis
A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
The purpose of the phase 2, GT-201 clinical study is to determine if GC4419 administered prior to intensity-modulated radiation therapy (IMRT) reduces the incidence, duration, and severity of radiation induced oral mucositis in…
- Trial name
- NCT02508389
- Testing
- Low Dose GC4419: 30mg/day, High Dose GC4419: 90mg/day, Intensity-Modulated Radiation Therapy
- Where
- 64 sites in United States, Canada and 1 more
- Volunteers
- 223 people
- Sponsor
- Galera Therapeutics, Inc.
Radiation-Induced Parotid Gland Hypofunction, Xerostomia Due to Radiotherapy
A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and Xerostomia
Open-label, non-randomized, dose escalation trial of AAV2hAQP1 administered via Stensen's duct to a single or both parotid glands in subjects with radiation-induced xerostomia The objectives are to evaluate the safety and…
- Conditions
- Radiation-Induced Parotid Gland Hypofunction, Xerostomia Due to Radiotherapy, Head and Neck Cancer
- Trial name
- NCT04043104
- Testing
- AAV2hAQP1: 1 x 10^11 vg/gland (single gland), AAV2hAQP1: 3 x 10^10 vg/gland (both glands), AAV2hAQP1: 3 x 10^11 vg/gland (single gland)
- Where
- 6 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- MeiraGTx UK II Ltd
Lung Cancer, Head and Neck Cancer
SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
Chemotherapy treatment with platinum based agents is well noted to cause ototoxicity. It is the objective of this study to determine the safety and efficacy of SPI-1005 at three dose levels when delivered orally twice daily for 3…
- Conditions
- Lung Cancer, Head and Neck Cancer, Hearing Loss, Ototoxicity
- Trial name
- NCT01451853
- Testing
- SPI-1005 Low Dose, SPI-1005 Middle Dose, SPI-1005 High Dose
- Where
- United States
- Sponsor
- Sound Pharmaceuticals, Incorporated
Radiation-induced Dermatitis
Clinical Trial to Evaluate Safety and Efficacy of Jalosome® Soothing Gel.
Primary objective To investigate the effectiveness of Jalosome® compared with placebo in the prevention and treatment of RID in patients with HNC undergoing RT.
- Trial name
- JALOSOME-01 (NCT05284487)
- Testing
- Jalosome® soothing gel
- Where
- Italy
- Volunteers
- 57 people
- Sponsor
- Welcare Industries SpA
Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia
This study will assess the long-term safety and efficacy of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
- Trial name
- NCT06544798
- Testing
- AAV2-hAQP1
- Where
- 8 sites in United States, Canada
- Volunteers
- 276 people
- Sponsor
- MeiraGTx, LLC